KalVista Secures $184M Financing for Sebetralstat Launch
Company Announcements

KalVista Secures $184M Financing for Sebetralstat Launch

KalVista Pharmaceuticals ( (KALV) ) has provided an update.

KalVista Pharmaceuticals has secured a significant up to $184 million synthetic royalty financing deal with DRI Healthcare Trust to fund the commercialization of sebetralstat, a novel oral therapy for hereditary angioedema (HAE). The agreement includes an initial $100 million upfront payment, potential milestone payments, and a tiered royalty structure based on global net sales. This strategic move strengthens KalVista’s financial position as it prepares for the anticipated U.S. launch of sebetralstat in 2025, potentially revolutionizing HAE treatment with an on-demand oral option.

See more data about KALV stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyKalVista enters synthetic royalty financing with DRI Healthcare Trust
TheFlyKalVista 5.5M share Secondary priced at $10.00
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App